Steve Williams joined SomaLogic in 2009 as chief medical officer. Steve trained as a physician at Charing Cross and Westminster medical school, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology. He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne. He joined Pfizer in the U.K. in 1989 in experimental medicine, and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin]. He moved to the U.S. in 1993 with Pfizer and worked in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury. He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was made vice president in 2006. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase III trials.